A Randomized Phase III Study Assessing the Efficacy and Safety of Olvi-Vec followed by Platinum-doublet Chemotherapy and Bevacizumab Compared with Platinum-doublet Chemotherapy and Bevacizumab in Women with Platinum-Resistant/Refractory Ovarian Cancer (OnPrime Study)
Details
A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec followed by Platinum-doublet Chemotherapy and Bevacizumab Compared with Platinum-doublet Chemotherapy and Bevacizumab in Women with Platinum-Resistant/Refractory Ovarian Cancer
Eligibility
You can join if...
Inclusion Criteria:
-Women >18 years old
History of histologically confirmed (from prior treatment) non-resectable ovarian, fallopian tube or primary peritoneal cancer.
-High-grade serous [including malignant mixed Mullerian tumor (MMMT) with metastasis that contains high grade epithelial carcinoma; FIGO grades 2 and 3 allowed], endometrioid, or clear-cell ovarian cancer.
Exclusion Criteria:
-History of thromboembolic event within the prior 3 months.
-Pregnant or breast-feeding women.
-Smallpox vaccination within 1 year of study therapy.